Subcutaneously delivered natalizumab for the treatment of highly active relapsing-remitting multiple sclerosis
2022
Abstract
4-integrin monoclonal antibody, indicated as a single disease modif ying therapy in adults with highly active relapsing-remitting multiple sclerosis. In 2021, natalizumab was authorized for use also as a subcutaneous injection.
Clinical trials have shown that monthly subcutaneous injections of natalizumab are as safe and clinically and radiologically effective as monthly intravenous infusions.aTherapeutic monoclonal antibodies (MAbs) have become one of the fastest growing classes of drugs, approved for the treatment of a wide range of indications. The development of new humanized and fully human MAbs has vastly improved their safety profile.
Natalizumab is a humanized anti-.